INO Stock — Inovio Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$1.24

Market cap

$128.2M

Cash

$55.0M

Enterprise value

$73.2M

Balance sheet

Cash	$55.0M
Debt	$0.0M
Net cash	$55.0M
Enterprise value	$73.2M
Basic shares	82.3M shares
Fully diluted shares	164.8M shares
Fully diluted market cap	$204.4M
Cash per share	$0.67

Cash figures as of 2026-07-31. Database snapshot: 2026-09-21.

Price history

Loading INO daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	INO-5401	Phase 1/2	Glioblastoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

INO-3107

Phase 2 · Active Modality: DNA medicine (drug-device combination with electroporation)

Aliases PAPZIMEOS

Target HPV-6 and HPV-11

Indications

recurrent respiratory papillomatosis (RRP) (Phase 2)

Status note Lead candidate. Completed Phase 1/2 trial in HPV-6/HPV-11-associated RRP (81.3% of patients had reduced surgical interventions in the year post-treatment). Company believes INO-3107 meets criteria for accelerated approval; not planning to seek BLA under traditional pathway (which could require a Phase 3 trial).

VGX-3100

Phase 3 · Active Modality: DNA medicine

Target HPV

Partnerships ApolloBio Corporation (exclusive right to develop and commercialize in agreed territories; up to $20.0M in regulatory milestones; tiered low-to-mid-teens royalties)

Indications

HPV-related pre-cancers (Phase 3)

Status note ApolloBio continues to conduct a Phase 3 trial in China and plans to seek regulatory approval and commercialize there. INOVIO is not pursuing VGX-3100 development itself in the excerpts.

INO-3112

Phase 3 · Active Modality: DNA immunotherapy

Target HPV-16/-18 E6/E7 + IL-12

Partnerships Coherus BioSciences (clinical collaboration and supply agreement, Jan 2024; INO-3112 + LOQTORZI combo)

Indications

Oropharyngeal squamous cell carcinoma (HPV-16/-18 positive) (Phase 3)

Status note 10-K: "DNA immunotherapy consisting of two plasmids targeting HPV-16 and HPV-18 E6 and E7 antigens combined with a DNA plasmid encoding for the human IL-12 cytokine." Planned Phase 3 with FDA alignment on design; Coherus supplies LOQTORZI. Phase 1/2a data published 2019.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	INO-5401
Lead indication	Glioblastoma
Lead phase	Phase 1/2
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT03491683	Phase 1/2	Active, not recruiting	Sponsor	Inovio Pharmaceuticals	—	Glioblastoma	—
NCT04367675	Phase 1	Active, not recruiting	Collaborator	Abramson Cancer Center at Penn Medicine	—	BRCA1/2 Mutation	—
NCT02772003	Phase 1	Active, not recruiting	Collaborator	National Cancer Institute (NCI)	—	Chronic Hepatitis; Hepatitis C Infection; Hepatocellular Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Inovio Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	2,143,910	+673,802	0.11%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

INO — Inovio Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders